PRDX1 and neoplasm: This finding further supports the conclusion that the sensitivity of EGFR-mutant cells to osimertinib markedly increased after PRDX1 inhibition compared to EGFR wild-type cells, suggesting that inhibition of PRDX1 has a synergistic effect with osimertinib in suppressing tumor growth.